Biotechnology
Gilead reported a net loss of $10.5 billion in Q2 FY2026 due to $12.9 billion in one-time charges, overshadowing 10% revenue growth from HIV and oncology products.
Key risk: Concentration risk in the HIV franchise
Gilead relies heavily on HIV product sales (over 70% of total product revenue). Loss of market share to generics or new competitors, or any disruption in the HIV portfolio, could materially harm the company.
Other Biotechnology companies